Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Dianabol and Masteron Interaction: Avoid | Peptide Database

Compound Profiles Dianabol Oral Anabolic Steroid | Classic Mass Builder Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-a

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Compound Profiles

Dianabol

Oral Anabolic Steroid | Classic Mass Builder

Dianabol exerts its effects primarily through binding to the androgen receptor (AR), promoting nitrogen retention, protein synthesis, and glycogenolysis in skeletal muscle tissue. Its 17-alpha-alkylated structure allows it to survive first-pass hepatic metabolism, enabling oral bioavailability but placing significant stress on the liver.

Masteron

DHT-Derived Anabolic Steroid | Hardening & Anti-Estrogenic

Drostanolone binds to the androgen receptor with high affinity, promoting protein synthesis and nitrogen retention in skeletal muscle. As a DHT derivative, it cannot be converted to estrogen by the aromatase enzyme, eliminating estrogen-related side effects such as water retention and gynecomastia from the compound itself.

Combined Organ Load

Shared Safety Flags

Frequently Asked Questions

Can I take Dianabol with Masteron?

Combining Dianabol with Masteron is not recommended. Both Dianabol and Masteron carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.

Is Dianabol and Masteron safe together?

This combination carries significant risk. Both Dianabol and Masteron carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended. Consult a healthcare professional before combining.

What are the interactions between Dianabol and Masteron?

Both Dianabol and Masteron carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended. This assessment has 60% confidence and is inferred from pharmacological mechanism analysis.

How should I time Dianabol and Masteron?

Dianabol has a half-life of ~4-6 hours and Masteron has a half-life of ~2 days (propionate), ~10 days (enanthate). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

comparison

What's the addiction risk of phenibut vs benzodiazepines?

Phenibut carries similar addiction and withdrawal risk to benzodiazepines despite not being a benzo. Physical dependence can develop in as little as 1-2 weeks of daily use, and withdrawal i…

Source: peptide-db.com
comparison

BPC-157 vs TB-500: Mechanisms, Dosing & the Wolverine Stack

How BPC-157 and TB-500 compare for healing: mechanism differences, dosing protocols, clinical evidence, and when to combine both in the Wolverine Stack.

Source: peptide-db.com
comparison

Why is TB-500 dosed 2.5x higher in Tri-Heal Max versus standard Wolverine Stack?

Tri-Heal Max emphasizes TB-500's superior cell migration and angiogenesis properties (25mg vs standard 10mg) for more significant tissue damage. The 2.5:1 ratio targets acute injuries, majo…

Source: peptide-db.com
Research context

Read sources and limitations before applying a claim.

Research Indications

FDA-approved for treatment of essential hypertension as monotherapy or in combination with other antihypertensives. Provides consistent 24-hour blood pressure reduction. Particularly effective for AAS-induced hypertension where elevated blood pressure is driven by RAAS activation and increased erythropoiesis. FDA-approved for reduction of cardiovascular morbidity in patients at high risk. The ONTARGET trial demonstrated non-inferiority to ramipril for the composite of cardiovascular death, MI, stroke, and hospitalization for heart failure in over 25,000 high-risk patients. Angiotensin II receptor blockade counteracts the pro-hypertrophic and pro-fibrotic effects of supraphysiological androgen levels on the myocardium. Preclinical and observational data support the use of ARBs to attenuate left ventricular hypertrophy in steroid users. Widely recommended in harm reduction protocols. Reduces intraglomerular pressure and proteinuria by blocking angiotensin II-mediated efferent arteriolar constriction. Slows progression of chronic kidney disease, particularly in patients with diabetic nephropathy or hypertensive nephrosclerosis. Relevant for AAS users where elevated blood pressure and NSAID co-use may compromise renal function. Telmisartan's partial PPAR-gamma agonism improves insulin sensitivity without the weight gain associated with full PPAR-gamma agonists like pioglitazone. May reduce the risk of new-onset diabetes in hypertensive patients. The metabolic benefit is particularly relevant for users of compounds that impair glucose tolerance (e.g., growth hormone, trenbolone).

Source: peptide-db.com ↗

Community Research

Join others researching PE-22-28 — share findings, ask questions, and learn from real experiences Synthetic heptapeptide derived from Spadin positions 22-28, functioning as potent TREK-1 antagonist with enhanced selectivity and duration versus parent compound. Primary research focus on rapid antidepressant effects. Selectively blocks TREK-1 potassium channels (IC50: 0.12 nM). Enhances serotonin neurotransmission in dorsal raphe nucleus, triggering CREB activation and hippocampal neurogenesis.

Source: peptide-db.com ↗
Practical and safety references

These excerpts are educational, not personalised medical instructions.

Dosage reference

Dosing Protocols

YK-11 is administered exclusively via the oral route. It is available as a liquid solution (typically in PEG-400 or similar carrier) or in capsule form from research chemical suppliers. Due to its 17-alpha alkylated steroidal structure, it has sufficient oral bioavailability to be effective when taken by mouth. The estimated half-life of 6-10 hours (based on structural analogy rather than pharmacokinetic studies) necessitates twice-daily dosing to maintain more stable plasma concentrations throughout the day. Research Dose - Conservative 5 mg/day (2.5 mg AM + 2.5 mg PM) Twice daily (split AM/PM) Oral (liquid or capsule) Research Dose - Moderate 10 mg/day (5 mg AM + 5 mg PM) Research Dose - Upper Range 15 mg/day (7.5 mg AM + 7.5 mg PM)

Source: peptide-db.com ↗
Side effects

Common Side Effects

Hypercalciuria (high calcium in urine) Dizziness Nausea Headache Palpitations Fatigue Upper abdominal pain Vertigo Injection site reactions

Source: peptide-db.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides